FDA Grants Orphan Status to Cellenkos’ CK0804 in Myelofibrosis
Cellenkos Inc., a clinical-stage biotechnology company developing off-the-shelf regulatory T cell (Treg) therapies, has received Orphan Drug Designation from the U.S. Food and Drug…
Read More...
Read More...
